Literature DB >> 29452636

Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling.

Tatiana Goncharov1, Stefanie Hedayati1, Melinda M Mulvihill2, Anita Izrael-Tomasevic3, Kerry Zobel1, Surinder Jeet4, Anna V Fedorova1, Celine Eidenschenk2, Jason deVoss4, Kebing Yu3, Andrey S Shaw5, Donald S Kirkpatrick3, Wayne J Fairbrother1, Kurt Deshayes1, Domagoj Vucic6.   

Abstract

Inflammatory responses mediated by NOD2 rely on RIP2 kinase and ubiquitin ligase XIAP for the activation of nuclear factor κB (NF-κB), mitogen-activated protein kinases (MAPKs), and cytokine production. Herein, we demonstrate that selective XIAP antagonism blocks NOD2-mediated inflammatory signaling and cytokine production by interfering with XIAP-RIP2 binding, which removes XIAP from its ubiquitination substrate RIP2. We also establish that the kinase activity of RIP2 is dispensable for NOD2 signaling. Rather, the conformation of the RIP2 kinase domain functions to regulate binding to the XIAP-BIR2 domain. Effective RIP2 kinase inhibitors block NOD2 signaling by disrupting RIP2-XIAP interaction. Finally, we identify NOD2 signaling and XIAP-dependent ubiquitination sites on RIP2 and show that mutating these lysine residues adversely affects NOD2 pathway signaling. Overall, these results reveal a critical role for the XIAP-RIP2 interaction in NOD2 inflammatory signaling and provide a molecular basis for the design of innovative therapeutic strategies based on XIAP antagonists and RIP2 kinase inhibitors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IAP antagonist; NOD2; RIP2; RIPK2; XIAP; inflammatory signaling; kinase inhibitor; ubiquitin

Mesh:

Substances:

Year:  2018        PMID: 29452636     DOI: 10.1016/j.molcel.2018.01.016

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  39 in total

1.  Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2.

Authors:  Madelyn H Miller; Michael G Shehat; Justine T Tigno-Aranjuez
Journal:  Immunohorizons       Date:  2020-12-18

2.  Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Authors:  Pamela A Haile; Linda N Casillas; Michael J Bury; John F Mehlmann; Robert Singhaus; Adam K Charnley; Terry V Hughes; Michael P DeMartino; Gren Z Wang; Joseph J Romano; Xiaoyang Dong; Nikolay V Plotnikov; Ami S Lakdawala; Maire A Convery; Bartholomew J Votta; David B Lipshutz; Biva M Desai; Barbara Swift; Carol A Capriotti; Scott B Berger; Mukesh K Mahajan; Michael A Reilly; Elizabeth J Rivera; Helen H Sun; Rakesh Nagilla; Carol LePage; Michael T Ouellette; Rachel D Totoritis; Brian T Donovan; Barry S Brown; Khuram W Chaudhary; Peter J Gough; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2018-09-26       Impact factor: 4.345

3.  RIP2 promotes FcγR-mediated reactive oxygen species production.

Authors:  Michael G Shehat; Omar A Cardona; George F Aranjuez; Mollie W Jewett; Justine T Tigno-Aranjuez
Journal:  J Biol Chem       Date:  2019-05-21       Impact factor: 5.157

4.  Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage.

Authors:  Amy C Hart; Lynn Abell; Junqing Guo; Michael E Mertzman; Ramesh Padmanabha; John E Macor; Charu Chaudhry; Hao Lu; Kevin O'Malley; Patrick J Shaw; Carolyn Weigelt; Matthew Pokross; Kevin Kish; Kyoung S Kim; Lyndon Cornelius; Andrew E Douglas; Deepa Calambur; Ping Zhang; Brian Carpenter; William J Pitts
Journal:  ACS Med Chem Lett       Date:  2019-05-06       Impact factor: 4.345

5.  Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.

Authors:  Chalada Suebsuwong; Bing Dai; Daniel M Pinkas; Anantha Lakshmi Duddupudi; Li Li; Joshua C Bufton; Lisa Schlicher; Mads Gyrd-Hansen; Ming Hu; Alex N Bullock; Alexei Degterev; Gregory D Cuny
Journal:  Eur J Med Chem       Date:  2020-05-15       Impact factor: 6.514

6.  Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Authors:  Curt D Haffner; Adam K Charnley; Christopher J Aquino; Linda Casillas; Máire A Convery; Julie A Cox; Mark A Elban; Nicole C Goodwin; Peter J Gough; Pamela A Haile; Terry V Hughes; Beth Knapp-Reed; Constantine Kreatsoulas; Ami S Lakdawala; Huijie Li; Yiqian Lian; David Lipshutz; John F Mehlmann; Michael Ouellette; Joseph Romano; Lisa Shewchuk; Arthur Shu; Bartholomew J Votta; Huiqiang Zhou; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2019-10-11       Impact factor: 4.345

Review 7.  Targeting intrinsic cell death pathways to control fungal pathogens.

Authors:  Madhura Kulkarni; Zachary D Stolp; J Marie Hardwick
Journal:  Biochem Pharmacol       Date:  2019-01-17       Impact factor: 5.858

8.  A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.

Authors:  John Silke; Ueli Nachbur; Valentin J Heim; Laura F Dagley; Che A Stafford; Fynn M Hansen; Elise Clayer; Aleksandra Bankovacki; Andrew I Webb; Isabelle S Lucet
Journal:  EMBO Rep       Date:  2020-09-21       Impact factor: 8.807

9.  Immunoblot Analysis of the Regulation of TNF Receptor Family-Induced NF-κB Signaling by c-IAP Proteins.

Authors:  Eugene Varfolomeev; Tatiana Goncharov; Domagoj Vucic
Journal:  Methods Mol Biol       Date:  2021

Review 10.  RIPK protein kinase family: Atypical lives of typical kinases.

Authors:  Gregory D Cuny; Alexei Degterev
Journal:  Semin Cell Dev Biol       Date:  2020-07-27       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.